Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Next Previous
Trial Profile

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zumilokibart (Primary) ; Lebrikizumab
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms APEX
  • Sponsors Apogee Therapeutics

Most Recent Events

  • 06 Jan 2026 According to an Apogee Therapeutics media release, Part A maintenance (52-week) data is expected in Q1 2026, with potential to support a best-in-class every 3- or 6-month dosing profile. Part B enrollment was completed ahead of schedule, exceeding the target with 347 patients, and the 16-week induction data readout is on track for Q2 2026.
  • 11 Sep 2025 According to an Apogee Therapeutics media release, company look forward to presenting these findings to the scientific community at EADV this year.
  • 11 Sep 2025 According to an Apogee Therapeutics media release, data from the phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis was accepted for a late-breaker oral presentation at the upcoming EADV Congress 2025, to be held in Paris, France from September 17-20, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top